{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:05:00Z","timestamp":1789563900826,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12776-w","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:17:31Z","timestamp":1789561051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated analysis of VEGFA rs833061 (\u2212\u2009460T\u2009>\u2009C) promoter polymorphism and serum YKL-40 levels in bladder cancer: evidence of a genotype\u2013phenotype association"],"prefix":"10.1007","volume":"53","author":[{"given":"Rohit","family":"Kaushik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devender","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Siwach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulshan","family":"Rohilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Narwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minakshi","family":"Vashist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"3","key":"12776_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"12776_CR2","first-page":"1","volume":"74","author":"MA Filho","year":"2025","unstructured":"Filho MA et al (2025) Bladder cancer incidence and mortality: A global overview based on GLOBOCAN 2022. Eur Urol Open Sci 74:1\u201310","journal-title":"Eur Urol Open Sci"},{"issue":"19","key":"12776_CR3","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD (2020) Bladder cancer: A review. JAMA 324(19):1980\u20131991. https:\/\/doi.org\/10.1001\/jama.2020.17598","journal-title":"JAMA"},{"issue":"1","key":"12776_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: New dimensions. Cancer Discov 12(1):31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059","journal-title":"Cancer Discov"},{"issue":"6","key":"12776_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N (2019) VEGF in signaling and disease: Beyond discovery and development. Cell 176(6):1248\u20131264. https:\/\/doi.org\/10.1016\/j.cell.2019.01.021","journal-title":"Cell"},{"issue":"10","key":"12776_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nrc909","volume":"2","author":"N Ferrara","year":"2002","unstructured":"Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2(10):795\u2013803. https:\/\/doi.org\/10.1038\/nrc909","journal-title":"Nat Rev Cancer"},{"key":"12776_CR7","first-page":"1189456","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang Y, Li X, Zhang H, Chen J (2023) VEGFA-mediated angiogenesis and its clinical significance in urological malignancies. Front Oncol 13:1189456","journal-title":"Front Oncol"},{"issue":"8","key":"12776_CR8","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1006\/cyto.2000.0692","volume":"12","author":"CJ Watson","year":"2000","unstructured":"Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12(8):1232\u20131235. https:\/\/doi.org\/10.1006\/cyto.2000.0692","journal-title":"Cytokine"},{"issue":"26","key":"12776_CR9","doi-asserted-by":"publisher","first-page":"e33967","DOI":"10.1097\/MD.0000000000034089","volume":"102","author":"H Qin","year":"2023","unstructured":"Qin H, Zhang X, Liu Y et al (2023) The relationship between VEGF \u2013\u2009460T\u2009>\u2009C polymorphism and cancer risk: A systematic review and meta-analysis based on 46 reports. Med (Baltim) 102(26):e33967","journal-title":"Med (Baltim)"},{"issue":"3","key":"12776_CR10","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3390\/ijms23031358","volume":"23","author":"M Stevens","year":"2022","unstructured":"Stevens M, Oltean S, Bates DO (2022) VEGF-A alternative splicing and its role in angiogenesis. Int J Mol Sci 23(3):1358. https:\/\/doi.org\/10.3390\/ijms23031358","journal-title":"Int J Mol Sci"},{"issue":"2","key":"12776_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/1055-9965.EPI-05-0011","volume":"15","author":"JS Johansen","year":"2006","unstructured":"Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA (2006) Serum YKL-40, a new prognostic biomarker in cancer patients. Cancer Epidemiol Biomarkers Prev 15(2):194\u2013202","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"12776_CR12","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3390\/cancers16050915","volume":"16","author":"MC Chang","year":"2024","unstructured":"Chang MC, Chen CA, Chen PJ, Chiang YC, Cheng WF (2024) The role of CHI3L1 (YKL-40) in cancer biology, tumor progression and therapeutic response. Cancers (Basel) 16(5):915. https:\/\/doi.org\/10.3390\/cancers16050915","journal-title":"Cancers (Basel)"},{"issue":"6","key":"12776_CR13","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00018-012-1141-5","volume":"70","author":"R Shao","year":"2013","unstructured":"Shao R (2013) YKL-40 acts as an angiogenic factor to promote tumor vascularization. Cell Mol Life Sci 70(6):1005\u20131015. https:\/\/doi.org\/10.1007\/s00018-012-1141-5","journal-title":"Cell Mol Life Sci"},{"issue":"7070","key":"12776_CR14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nature04478","volume":"438","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438(7070):932\u2013936. https:\/\/doi.org\/10.1038\/nature04478","journal-title":"Nature"},{"issue":"19","key":"12776_CR15","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbel","year":"2008","unstructured":"Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039\u20132049. https:\/\/doi.org\/10.1056\/NEJMra0706596","journal-title":"N Engl J Med"},{"issue":"11","key":"12776_CR16","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm.2537","volume":"17","author":"SM Weis","year":"2011","unstructured":"Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17(11):1359\u20131370. https:\/\/doi.org\/10.1038\/nm.2537","journal-title":"Nat Med"},{"issue":"9","key":"12776_CR17","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano R, Ramachandran M, Dimberg A (2020) Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 77(9):1745\u20131770. https:\/\/doi.org\/10.1007\/s00018-019-03351-7","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"12776_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1159\/000054076","volume":"37","author":"W Renner","year":"2000","unstructured":"Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936\u00a0C\/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37(6):443\u2013448. https:\/\/doi.org\/10.1159\/000054076","journal-title":"J Vasc Res"},{"issue":"2","key":"12776_CR19","first-page":"172","volume":"53","author":"JS Johansen","year":"2006","unstructured":"Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53(2):172\u2013209","journal-title":"Dan Med Bull"},{"key":"12776_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-1-59745-447-6_7","volume":"511","author":"A Roslind","year":"2009","unstructured":"Roslind A, Johansen JS (2009) YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol 511:159\u2013184. https:\/\/doi.org\/10.1007\/978-1-59745-447-6_7","journal-title":"Methods Mol Biol"},{"key":"12776_CR21","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.3389\/fimmu.2019.02346","volume":"10","author":"S Libreros","year":"2019","unstructured":"Libreros S, Garcia-Areas R, Shibata Y, Carrio R, Torroella-Kouri M (2019) Emerging role of CHI3L1 in cancer and inflammation: current perspectives. Front Immunol 10:2346. https:\/\/doi.org\/10.3389\/fimmu.2019.02346","journal-title":"Front Immunol"},{"issue":"50","key":"12776_CR22","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1038\/onc.2009.292","volume":"28","author":"R Shao","year":"2009","unstructured":"Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W (2009) YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28(50):4456\u20134468. https:\/\/doi.org\/10.1038\/onc.2009.292","journal-title":"Oncogene"},{"issue":"5","key":"12776_CR23","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1535-7163.MCT-10-0868","volume":"10","author":"M Faibish","year":"2011","unstructured":"Faibish M, Francescone R, Bentley B, Yan W, Shao R (2011) A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther 10(5):742\u2013751. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0868","journal-title":"Mol Cancer Ther"},{"issue":"Pt 1","key":"12776_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1042\/BJ20020075","volume":"365","author":"AD Recklies","year":"2002","unstructured":"Recklies AD, White C, Ling H (2002) The chitinase 3-like protein human cartilage glycoprotein-39 stimulates proliferation of human connective tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 365(Pt 1):119\u2013126. https:\/\/doi.org\/10.1042\/BJ20020075","journal-title":"Biochem J"},{"issue":"30","key":"12776_CR25","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1038\/onc.2011.48","volume":"30","author":"RA Francescone","year":"2011","unstructured":"Francescone RA, Scully S, Bentley B, Yan W, Taylor SL, Oh D, Moral L, Shao R (2011) Glioblastoma-derived YKL-40 promotes angiogenesis and activates endothelial cells in the tumor microenvironment. Oncogene 30(30):3363\u20133374. https:\/\/doi.org\/10.1038\/onc.2011.48","journal-title":"Oncogene"},{"key":"12776_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-3-0348-0837-8_11","volume":"816","author":"R Shao","year":"2014","unstructured":"Shao R (2014) YKL-40 and tumor angiogenesis. Adv Exp Med Biol 816:265\u2013276. https:\/\/doi.org\/10.1007\/978-3-0348-0837-8_11","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"12776_CR27","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1189\/jlb.3VMR0415-142R","volume":"98","author":"S Libreros","year":"2015","unstructured":"Libreros S, Iragavarapu-Charyulu V (2015) YKL-40\/CHI3L1 drives inflammation on the road of tumor progression. J Leukoc Biol 98(6):931\u2013936","journal-title":"J Leukoc Biol"},{"key":"12776_CR28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-physiol-012110-142250","volume":"73","author":"CG Lee","year":"2011","unstructured":"Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, He CH, Takyar S, Elias JA (2011) Role of chitin and chitinase\/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 73:479\u2013501. https:\/\/doi.org\/10.1146\/annurev-physiol-012110-142250","journal-title":"Annu Rev Physiol"},{"key":"12776_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","volume":"10","author":"C Lee","year":"2025","unstructured":"Lee C, Kim MJ, Kumar A, Lee HW, Yang Y et al (2025) Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives. Signal Transduct Target Ther 10:170. https:\/\/doi.org\/10.1038\/s41392-025-02249-0","journal-title":"Signal Transduct Target Ther"},{"key":"12776_CR30","doi-asserted-by":"publisher","first-page":"1453278","DOI":"10.3389\/fonc.2024.1453278","volume":"14","author":"M Ahangar","year":"2024","unstructured":"Ahangar M, Mahjoubi F, Mowla SJ (2024) Bladder cancer biomarkers: current approaches and future directions. Front Oncol 14:1453278. https:\/\/doi.org\/10.3389\/fonc.2024.1453278","journal-title":"Front Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12776-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12776-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12776-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:17:33Z","timestamp":1789561053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12776-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12776"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12776-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"13 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Human Ethics Committee, Maharshi Dayanand University, Rohtak, Haryana, India (Approval No. HEC\/2023\/34).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final manuscript for publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants included in the study.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1585"}}